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DOI 10.1016/j.cmet.2011.06.018SUMMARY loss of b cell mass by apoptosis (Donath and Halban, 2004;Decreased b cell mass and function are hallmarks of
type 2 diabetes. Here we identified, through a siRNA
screen, beta site amyloid precursor protein cleaving
enzyme 2 (Bace2) as the sheddase of the proprolifer-
ative plasma membrane protein Tmem27 in murine
and human b cells. Mice with functionally inactive
Bace2 and insulin-resistantmice treatedwith a newly
identified Bace2 inhibitor both display augmented
b cell mass and improved control of glucose homeo-
stasis due to increased insulin levels. These results
implicate Bace2 in the control of b cell maintenance
and provide a rational strategy to inhibit this pro-
tease for the expansion of functional pancreatic
b cell mass.
INTRODUCTION
Type 2 diabetes is characterized by hyperglycemia resulting
from an inability of the endocrine pancreas to secrete sufficient
insulin to meet the increased metabolic demands that are asso-
ciated with insulin resistance (Kahn et al., 2006). Two defects
have consistently been reported in patients with type 2 diabetes:
gradual deterioration of b cell function and a reduction in pancre-
atic b cell mass. The molecular mechanisms leading to b cell
failure in type 2 diabetes are incompletely understood, but
several lines of evidence suggest that mitochondrial dysfunction,
oxidative and ER stress, dysfunctional fatty acid metabolism,
glucolipotoxicity, and amyloid deposition contribute to b cell
demise and ultimately result in functional b cell alterations andCell MeKahn et al., 2006).
The plasma membrane (PM) of pancreatic b cells is a highly
specialized compartment regulating a variety of processes
pivotal to proper b cell function. Due to its accessibility, the
PM is also rich in pharmacological targets such as ion chan-
nels, transporters, and growth factor receptors. Many of these
cell surface and secreted factors are critically dependent on the
activity of proteases, which contribute to autocrine and para-
crine shedding of growth factors and their receptors as well
as to regulating extracellular matrix turnover. Tmem27 (also
termed collectrin), a 46 kDa type I transmembrane protein, is
a homolog of the noncatalytic domain of angiotensin-convert-
ing enzyme-related carboxypeptidase (Ace2). Its expression
has only been reported in the brush border membrane of the
proximal tubules and collecting ducts of the kidney (Zhang
et al., 2001) and in the pancreatic b cell (Akpinar et al., 2005).
Tmem27 was first identified in the kidney by virtue of its upre-
gulation in hypertrophic kidneys after renal ablation (Zhang
et al., 2001). In this organ, Tmem27 stabilizes apical amino
acid transporters and is essential for amino acid reabsorption
(Danilczyk et al., 2006; Malakauskas et al., 2007). In pancreatic
islets Tmem27 was initially recognized as one of the most
strongly regulated targets of the transcription factor Tcf1
(HNF1a), mutations of which lead to the most common form
of maturity onset diabetes of the young (MODY3) (Shih et al.,
2001). Functionally, overexpression of Tmem27 in b cells leads
to increased proliferation in vitro and increased pancreatic
b cell mass in vivo (Akpinar et al., 2005). In another study, over-
expression of Tmem27 was reported to augment glucose-
stimulated insulin secretion (GSIS) (Fukui et al., 2005). The
abundance of Tmem27 protein in b cells is furthermore regu-
lated by ectodomain cleavage, which leads to two cleavagetabolism 14, 365–377, September 7, 2011 ª2011 Elsevier Inc. 365
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extracellular space (the shed fragment), and a 22 kDa
C-terminal fragment (CTF) remaining in the membrane that is
rapidly degraded (Akpinar et al., 2005). This shedding process
inactivates Tmem27, since neither the shed nor the CTF frag-
ment of Tmem27 had mitogenic activity.
The restricted expression of Tmem27 and its growth-
promoting and insulin-stimulatory activity in pancreatic b cells
coupled to a mechanism of inactivation in b cells by ectodomain
shedding led us to hypothesize that increasing Tmem27 levels
by targeting its protease may have beneficial consequences
for b cell function and growth. In the experiments described
here, the Tmem27 cleavage process served as a readout to iden-
tify the Tmem27 sheddase and determine whether genetic or
pharmacological inhibition of this protease mimics the effects
of Tmem27 overexpression in vivo.
RESULTS
Identification of Bace2 as the Tmem27 Sheddase
To identify the protease that cleaves Tmem27, we performed
a 35-compound protease inhibitor screen, in which all major
classes of proteases were targeted, and assayed for a decrease
in shed Tmem27 from the mouse insulinoma cell line MIN6. Cells
were cultured in the presence of the inhibitor or control vehicle,
and shed Tmem27 in the supernatant (SN) was measured by
immunoblotting. Several compounds of the aspartyl protease
inhibitor class showed inhibitory activity (see Figures S1A and
S1B available with this article online). We also executed a siRNA
screen targeting 29 abundant b cell surface proteases by trans-
fecting MIN6 cells and measuring N-terminal, shed Tmem27 in
the SN after 24 hr. The localization of the proteases to the cell
surface was confirmed by live cell protein N-glycocapture
(Wollscheid et al., 2009) followed by mass spectrometry (MS)
(data not shown). Silencing of Bace2 by RNA interference
(RNAi) resulted in a marked reduction of Tmem27 in the SN,
similar to control transfections in which Tmem27 was silenced
(Figure 1A). Inhibition of other proteases had no comparable
effect on Tmem27 shedding. Full-length (FL) Tmem27 in the cor-
responding cell lysates (CLs) was approximately three times
higher in cells treated with different siRNAs against Bace2
compared to control cells, indicating that the absence of
Bace2 stabilizes Tmem27 (Figure 1B). Tmem27 transcript levels
were unaltered upon inactivation of Bace2 by RNAi, demon-
strating that Tmem27 stabilization occurred posttranscriptionally
(Figure 1C). Since most known substrates of Bace2 are also
targets of its homolog Bace1, we also measured Tmem27 levels
in cells in which Bace1 was inactivated by RNAi. The amount of
Tmem27 in CL and SN was similar in cells treated with Bace1
and control siRNAs (Figure 1D), ruling out any significant contri-
bution of Tmem27 shedding by endogenous Bace1 in MIN6
cells. Furthermore, increased expression of human Bace2
(hBace2) led to enhanced shedding of Tmem27 and decreased
levels of the FL protein, but ectopic hBace1 did not affect
Tmem27 (Figure 1E), thereby further validating that Tmem27 is
regulated by Bace2 but not Bace1. Finally, we asked whether
the de novo expression of Bace2 was sufficient to induce
Tmem27 cleavage in HEK293 cells, a cell line that expresses
neither Bace2 (Figure 1F) nor Tmem27 (Akpinar et al., 2005).366 Cell Metabolism 14, 365–377, September 7, 2011 ª2011 ElsevieUpon coexpression of hTmem27 and hBace2, the shed fragment
of hTmem27 appeared in the SN, and FL hTmem27 was desta-
bilized (Figure 1F).
The previously described Bace1/2 substrates are structurally
diverse type I transmembrane proteins that are subject to subse-
quent intramembrane cleavage by the g-secretase complex
(Francis et al., 2002) (Figure 1G). In order to establish the extent
to which Tmem27 behaves like a canonical Bace1/2 substrate,
we determined whether the CTF of Tmem27, generated by
Bace2 cleavage, was also a substrate of the g-secretase com-
plex. Indeed, incubation ofMIN6 cells with increasing concentra-
tions of g-secretase inhibitor DAPT (Zhao et al., 2008) led to the
stabilization of a 22 kDa CTF in the CL (Figure 1H).
Peptides based on the amyloid precursor protein (APP)
cleavage sites have previously been used in biochemical assays
to evaluate Bace1 inhibitors (Turner et al., 2001). To charac-
terize a Tmem27 sequence that could serve as a Bace2 selec-
tive substrate, we mapped the Bace2 cleavage sites. Two
complementary approaches were taken, one to identify the N
terminus of the CTF, and one to determine the C terminus of
the shed fragment of Tmem27. To enrich for the CTF, MIN6 cells
overexpressing hTmem27 with a shortened cytosolic tail
(hTmem27-D171-222-V5) were incubated with DAPT. The
17 kDa CTF was isolated (Figure 2A), digested, and analyzed
by MS. Two peptides corresponding to the N terminus of the
CTF were identified, starting with F117 (site I) or N119 (site II).
These peptides were not detected in a FL hTmem27 control
sample (Figure 2B). To map the C terminus of the shed part of
Tmem27, the SN of MIN6 cells was collected and its digest sub-
jected to MS. A peptide ending at F125 was detected (site III;
Figure 2C) and was highly enriched in the SN when hBace2
was overexpressed in MIN6 cells, indicating that site III is
a true Bace2 cleavage site as well. These three Tmem27
cleavage sites (Figure 2D) are relatively conserved among
different species (Figure 2E) and resemble described Bace2
sites (Farzan et al., 2000; Hussain et al., 2000, 2001; Kuhn
et al., 2007; Turner et al., 2002; Yan et al., 2001), which can
be grouped into sites where cleavage occurs between a Leu
and an Ala/Asp/Asn residue (Figure 2E, indicated in red) and
sites cleaved between Phe and a hydrophobic residue (Fig-
ure 2E, indicated in blue). Taken together, these findings
demonstrate that Tmem27 expression in MIN6 cells is regulated
through ectodomain shedding by Bace2 and subsequent
cleavage of the CTF by g-secretase.
Tissue Distribution and Cellular Localization of Bace2
and Tmem27
Bace2 transcripts have previously been reported in multiple
tissues, including the pancreas and kidney, the two main sites
of Tmem27 expression (Bennett et al., 2000). To determine
the relative abundance of Bace2 mRNA, we assayed for the
presence of Bace2 transcripts in 27 mouse organs by real-
time PCR. Bace2 mRNA expression was highest in pancreatic
islets; was expressed at much lower levels in the pituitary,
colon, and ovaries; and was virtually absent from all the other
tissues (Figure S2A). In contrast, Bace1 mRNA displayed a
much broader tissue distribution. Bace2 transcript levels also
correlated with Bace2 protein expression in these tissues
(Figure S2B).r Inc.
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Figure 1. Identification of Bace2 as the Protease Cleaving Tmem27
(A) Quantification of shed Tmem27 in MIN6 supernatant (SN) upon siRNA treatment (n = 4). Signals were normalized to mean screen signal.
(B) Western blot for Tmem27 and Bace2 in MIN6 cell lysate (CL) and SN upon transfection with three different siBace2 (siBace2#1, 2, 3) and control sequences
(siCtrl#1, 2). Supernatants were collected for 24 hr starting 12 hr after transfection.
(C) Quantitative PCR analysis of cDNA from MIN6 cells transfected with siBace2 or control siRNA (n = 3).
(D) Western blot for Tmem27 and Bace1 in MIN6 CL and SN upon transfection with two different siBace1 and scrambled control (Ctrl) sequences.
(E) Western blot for Tmem27, Bace1, and Bace2 in MIN6 CL and SN upon transfection with hBace1 or hBace2 expression plasmids.
(F) Immunoblot for Tmem27 in HEK293 CL and SN upon transfection with N-terminally HA-tagged and C-terminally V5-tagged hTmem27 alone or cotransfection
with hBace2.
(G) Schematic representation of Tmem27 and its putative cleavage sites by Bace2 and g-secretase.
(H) Western blot for full-length (FL) Tmem27 and its C-terminal fragment (CTF) in MIN6 CL upon 16 hr treatment with g-secretase inhibitor DAPT. Data represent
means ± SD. *p% 0.05; **p% 0.01; ***p% 0.001.
Cell Metabolism
b Cell Protease Bace2
Cell Metabolism 14, 365–377, September 7, 2011 ª2011 Elsevier Inc. 367
0 5 10 15 20 25 30 35 40 45 50 55
20
40
60
80
100
20
40
60
80
100
20
40
60
80
100
Re
lat
i ve
Ab
un
da
nc
e 20
40
60
80
100
FLNDQTLEFLK
NDQTLEFLK
NRINNAFFLNDQTLEFLK
Reference peptide
0 5 10 15 20 25 30 35 40 45 50 55
FLNDQTLEFLK
NDQTLEFLK
NRINNAFFLNDQTLEFLK
Reference peptide
*** * *
*
Retention time (min)Retention time (min)
22 kDa
46 kDa
17 kDa
34 kDa
FL
Tmem27
CTF
Tmem27
γ-tubulin 48 kDa
hTm
em2
7de
l 171
-22
2V
5
hTm
em2
7V5
A B
Site 1 NH2-RMNKNRINNAFFLNDQTLEFLKIPSTLAPP…TMD-COOH
Site 3 NH2-RKNRNRINSAFFLDDHTLEFLKIPSTLAPP…TMD-COOH
Site 2 NH2-RMNKNRINNAFFLNDQTLEFLKIPSTLAPP…TMD-COOH
NH2-RMNKNRINNAF/FL/NDQTLEF/LKIPSTLAPP…TMD-COOH
site I site IIIsite II
D
NH2-… SEVKMDAEFRHDSGYEVHHQK / LVF / F / AEDVGSNK-TMD…COOH
NH2-… PAERHADGLAL / ALEPALASPAGAANF / L / AMVD…TMD…COOH
NH2-… SEVL / DAEFRHDSGYEVHHQK / LVF / F / AEDVGSNK-TMD…COOH
NH2-…RMNKNRINNAF / FL / NDQTLEF / LKIPSTLAPPMDPSVPI-TMD…COOH
NH2-…RKNRNRINSAF / FL / DDHTLEF / LKIPSTLAPPMEPSVPV-TMD…COOH
H. sapiens TMEM27
M. musculus TMEM27
APP SWEDISH MUTANT
APP
BACE2 prodomain
NH2-…KCVVHNTLSF/ QTLRTTVKEASSTFS-TMD…COOHIL-1R2
NH2-…RNERNRINSAF / LL / DDKTLEF / VQIPPTLAPATQTSSSS-TMD…COOH
NH2-…RQSKHRINNAF / LL / SDMTLEF / VGVPPTLAVPIQYNTPP-TMD…COOH
NH2-…RMNRNRINNAF / FL / NDQTLEF / LRIPSTLAPPTDPSVPI-TMD…COOHB. taurus TMEM27
X. tropicalis TMEM27
D. rerio TMEM27
C
E
Retention time (min)
R
el
at
iv
e
A
bu
nd
an
ce
51.5 52.0 52.5 53.0 53.5 54.0
Bace2
B2 DM
MIN6
100
80
60
40
20
0
i
Figure 2. Identification of the Bace2 Cleavage Site in Tmem27
(A) Western blot for Tmem27 in CL from MIN6 expressing either hTmem27D171-222-V5 or hTmem27-V5.
(B) Extracted ion chromatograms of Tmem27 peptides found in the Lys-C digest of the hTmem27D171-222-V5 CTF (left) and full-length (FL) hTmem27D171-222-
V5 (right). Asterisks indicate additional spectral peaks.
(C) Extracted ion chromatograms of Tmem27 peptide ‘‘INSAFFLDDHTLEF’’ found in the trypsin digest of the SN fromMIN6 cells stably transfected with plasmids
pcDNA3 (MIN6), hBace2 (Bace2), or catalytically inactive hBace2 D93A-D303A (B2DM).
(D) Amino acid sequence of the Tmem27 cleavage site region with peptides identified and representing sites I, II, and III highlighted. Note that site III was not seen
in the CTF digest because the resulting L126-K127 dipeptide is short and likely lost during sample preparation; the peptides ending at sites I and II could not be
observed in the digest of the shed Tmem27 due to the lack of charged residues.
(E) Alignment of the Tmem27 cleavage site region from different species and comparison to other reported Bace2 cleavage sites.
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b Cell Protease Bace2To determine the site of Bace2 presence within the islet,
pancreatic sections were costained for Bace2 and insulin,
glucagon, somatostatin, and pancreatic polypeptide (PP), as
markers for b, a, d, and PP cells, respectively. In line with recent
findings (Finzi et al., 2008), Bace2 signals were solely obtained
from insulin-positive cells (Figure 3A). Bace2 appeared to reside
mainly in intracellular vesicles that were distinct from insulin
granules, as the stainings were nonoverlapping (Figure 3B). To
obtain better space resolution, we ectopically expressed
hBace2 in MIN6 cells and found the site of localization to be368 Cell Metabolism 14, 365–377, September 7, 2011 ª2011 Elseviemainly the PM, similar to hTmem27 stainings (Figure 3C). Mouse
pancreatic sections were also stained for Bace2 and Tmem27,
and the two proteins colocalized (Figure 3D). The site of coexis-
tence was confirmed to be the PM, as both proteins peaked with
E-cadherin, a cell surface marker, on a sucrose density gradient
(Figure 3E). We also confirmed that Bace2 expression was
confined to b cells in humans (Figure S3A). Lastly, to assess if
Bace2 and its target Tmem27 are expressed in type 2 diabetic
(T2D) patients, we stained pancreatic tissue arrays. In line
with a recent report (Altirriba et al., 2010), we found reducedr Inc.
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Figure 3. Localization of Bace2 with
Respect to Tmem27 in Murine and Human
Islets
(A) Immunofluorescence images of murine islets
stained for Bace2 and insulin, glucagon, somato-
statin, and pancreatic polypeptide (PP). Scale bar,
50 mm.
(B) Image of a murine b cell stained for Bace2
(green) and insulin (red). Scale bar, 10 mm.
(C) 633 immunofluorescence images of MIN6 cells
stained for hBace2 (top panel) or hTmem27
(bottom panel) after transfection with either control
(pcDNA3) or the respective expression vector.
(D) Image of murine islets stained for Bace2 and
Tmem27. Scale bar, 50 mm.
(E) Subcellular fractionation by 10%–70% sucrose
gradient ultracentrifugation of MIN6 cells and
quantification of b cell proteins by ELISA and im-
munoblot analysis. Fractions correspond to 2.5%
sucrose density increments (fraction 1 = 10%,
fraction 24 = 70%).
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b Cell Protease Bace2Tmem27 protein in T2D. Furthermore, no changes in Bace2
expression were observed between control and T2D subjects
(Figures S3B–S3D, Table S1). These data indicate that the
Bace2/Tmem27 axis is preserved in humans.
Tmem27 Is a Bace2-Specific Substrate in b Cells
To substantiate the evidence that Bace2 is the main protease
cleaving Tmem27 in vivo, mice with an in-frame deletion of
exon 6 of Bace2 on both alleles (Bace2DE6/DE6) were used for
further studies (Dominguez et al., 2005). The deletion of exon
6, which encodes 30 amino acids including the Asp303 residue
involved in catalysis, has been predicted to impair the catalytic
activity of Bace2 (Dominguez et al., 2005). The inactivity of
Bace2DE6was confirmed inMIN6 cells andHEK293 cells, where
its overexpression had no effect on Tmem27 levels (Figures S4A
and S4B). However, Bace2DE6 was still able to bind Tmem27 in
a coimmunoprecipitation experiment, but contrary to wild-type
Bace2 was unable to destabilize Tmem27 (Figure S4C).
We next compared the levels of shed and FL Tmem27 in
the cell culture SN and CLs of size-matched pancreatic isletsCell Metabolism 14, 365–377, Sisolated from Bace2DE6/DE6 mice and
wild-type littermates. The medium of
Bace2DE6/DE6 islets after a 24 hr incuba-
tion period contained almost no de-
tectable levels of shed Tmem27 com-
pared to the wild-type control media,
while FL Tmem27 was greatly enriched
in CL of Bace2DE6/DE6 islets (Figure 4A).
To unambiguously exclude the possibility
that Bace1 participates in Tmem27 pro-
cessing, the same experiment was per-
formed with islets of Bace1–/– mice and
wild-type littermates. Intriguingly, the
Tmem27 levels in Bace1–/– islet lysates
were augmented compared to wild-type
lysates (Figure 4B). However, because
the Tmem27 ectodomain in the SN wasequally elevated, while the Bace2 levels were unchanged, this
increase of Tmem27 appeared to be independent of direct
cleavage. Finally, cleavage of overexpressed Tmem27 by kidney
cells has recently been reported (Altirriba et al., 2010). To test if
Bace2 or Bace1 affected kidney Tmem27 cleavage, we
measured FL Tmem27 levels in fresh kidney extracts from
Bace2DE6/DE6 or Bace1 null mice and wild-type littermates.
Kidney Tmem27 levels were similar in Bace2DE6/DE6 or
Bace1–/– and control mice (Figures 4C and 4D), a finding that is
consistent with the absence of Bace2 protein in the kidney
(Figures S2A and S2B) and the lack of endogenous Tmem27
cleavage fromdispersed kidneys (Akpinar et al., 2005). Together,
these results demonstrate that Bace2 is the main protease
cleaving Tmem27 in primary pancreatic b cells.
Bace2DE6/DE6 Mice Exhibit Reduced Blood Glucose
Levels, Improved Intraperitoneal Glucose Tolerance,
and Increased b Cell Mass
Overexpression of Tmem27 in the b cell leads to b cell expansion
and improved glucose homeostasis (Akpinar et al., 2005; Fukuieptember 7, 2011 ª2011 Elsevier Inc. 369
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Figure 4. Identification of Bace2 as the Tmem27
Sheddase in Primary b Cells
(A) Western blot for Tmem27 and Bace2 in CL and SN
of 100 isolated islets per lane from 15-week-old
Bace2DE6/DE6 mice and Bace2+/+ littermates.
(B) Western blot for Tmem27, Bace1, and Bace2 in CL and
SN of 100 isolated islets per lane from 15-week-old
Bace1–/– mice and Bace1+/+ littermates. All islets were
incubated in Opti-MEM for 48 hr.
(C) Immunoblot for Tmem27 and g-tubulin in fresh kidney
protein extracts from 15-week-old Bace2DE6/DE6 and
Bace2+/+ littermates.
(D) Western blot analysis of Tmem27 and g-tubulin in fresh
kidney protein extracts of 15-week-old Bace1–/–mice and
Bace1+/+ littermates.
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b Cell Protease Bace2et al., 2005). We therefore investigated if the absence of active
Bace2 leads to measurable changes in metabolism. Plasma
glucose levels of ad libitum-fed Bace2DE6/DE6 mice and wild-
type littermate controls were monitored up to the age of
16 weeks. No differences in body weight were measured in the
two genotypes (Figure 5A), yet Bace2DE6/DE6 animals displayed
persistently reduced blood glucose levels from the age of about
8 weeks on (Figure 5B). To study if Bace2DE6/DE6 animals ex-
hibited improved performance in a hyperglycemic setting, the
two groups were challenged with an intraperitoneal (i.p.) glucose
tolerance test (IPGTT). Bace2DE6/DE6 mice displayed lower
blood glucose levels in the fasted state and during the
IPGTT compared to wild-type mice (Figure 5C), indicating that
these mice clear glucose from the circulation more efficiently.
Plasma insulin levels after a 6 hr fast and 15 min after a glucose
injection were increased in Bace2DE6/DE6 compared to control
mice (Figure 5D), while fasting glucagon levels remained unal-
tered (33.9 ± 4.3 pg/ml and 30.3 ± 4.7 pg/ml in Bace2DE6/DE6
and wild-type mice, respectively). Furthermore, isolated
Bace2DE6/DE6 islets secreted more insulin when exposed to
glucose for 30min in a glucose stimulated insulin secretion assay
(GSIS) than did size-matched islets from wild-type mice (Fig-
ure 5E), demonstrating that the improved glucose tolerance
was in part explained by an increased insulin secretory capacity of
Bace2DE6/DE6 islets. Increased insulin sensitivity ofBace2DE6/ DE6
mice was ruled out by an insulin tolerance test (ITT), in which
mutant and control animals behaved similarly (Figure 5F).
In order to test if inactivation of Bace2 also has an effect
on pancreatic b cell growth, we measured the b cell mass and
total pancreatic insulin content in 20-week-old Bace2DE6/DE6
and control mice. The pancreatic b cell mass increased approx-
imately 30% in pancreata of Bace2DE6/DE6 animals compared to
wild-type littermates (Figure 5G), as did the pancreatic insulin
content (Figure 5H). In contrast, no changes were measured
for a cell mass (Figure 5I), as well as d and PP cell mass (data
not shown). To establish whether the increased b cell mass
was due to accelerated b cell proliferation, the percentage of
cells expressing Ki67, a proliferation marker, was determined370 Cell Metabolism 14, 365–377, September 7, 2011 ª2011 Elsevier Inc.(Figure 5J). Since Bace2DE6/DE6 mice had
approximately twice as many Ki67-positive
b cells and no apoptosis was observed in the
islets (data not shown), the increase in b cell
mass is most likely due to an increase in b cellproliferation. Finally, to assess if this proliferative effect of genetic
Bace2 inactivation was cell autonomous, the EdU incorporation
into insulin-positive cells within dispersed islets (Parnaud et al.,
2008) from Bace2DE6/DE6 and wild-type littermate was deter-
mined and found to be increased 1.5-fold (Figure 5K). Taken
together, Bace2DE6/DE6 mice exhibit improved glucose homeo-
stasis that correlates with increased insulin secretory capacity
of islets and augmented b cell proliferation and mass. Therefore,
the metabolic phenotype of Bace2DE6/DE6 mice demonstrates
that inactivation of Bace2 is beneficial for b cell function.
Identification and Characterization of a Bace2 Inhibitor
To further corroborate the role of Bace2 in vitro and in vivo, the
effective inhibitory concentrations (IC50) of five structurally
diverse Bace inhibitors, compounds A, B, C, D, and J, toward
Bace1, Bace2, and the related aspartyl protease CathepsinD
(CTSD) were determined in a Tmem27 and APP cleavage
site sequence-based FRET assay (Table S2). Using FRET
peptides QTLEFLKIPS and SEIDLMVLDR, corresponding to
the hTmem27 cleavage site III (Figure 2E) and the APP cleavage
site, respectively, compound J (CpdJ) was superior over
compounds A, B, C, and D in terms of potency of Bace2 inhibi-
tion and selectivity over CTSD (Table S2). Of note, compound D
has recently been described as a Bace2 inhibitor in the pancre-
atic b cell (Bettegazzi et al., 2010), yet no activity toward Bace1
or Bace2 was observed in our assay. All compounds except
compound D inhibited Tmem27 shedding in MIN6 cells and re-
sulted in the stabilization of this substrate in vitro, and none
except compound D induced apoptosis, as measured by active
caspase-3 immunoblotting (Figures S5A and S5B). Interestingly,
treatment with effective Bace2 inhibitors led to the appearance
of a higher molecular band in immunoblots, demonstrating that
they blocked the autocatalytic prodomain cleavage that is
essential for the conversion of the Bace2 zymogen to fully active,
mature form and indicative of Bace2 targeting. On the basis of
the superior activity and selectivity for Bace2 as well as favorable
in vivo pharmacokinetic (PK) properties (data not shown), CpdJ
was chosen for further evaluation.
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tion of Tmem27 was dependent on Bace2, we studied the effect
of CpdJ in primary islets of wild-type and Bace2DE6/DE6 animals
by western blotting. Wild-type islets treated with CpdJ exhibited
a substantial loss of Tmem27 ectodomain-shedding activity and
stabilization of FL Tmem27 in the CL (Figure 6A). In contrast, no
further changes of shed Tmem27 or FL Tmem27 in total CL were
observed upon CpdJ treatment of Bace2DE6/DE6 islets. Further-
more, CpdJ did not induce a Bace2 prodomain shift in these
islets, indicating that Bace2DE6 is not a target for CpdJ (Fig-
ure 6A). Finally, to study the effect of CpdJ on Tmem27 levels
and Bace2 inactivation in a time-dependent manner in vitro,
we incubated isolated mouse islets with CpdJ for up to 72 hr
and measured Tmem27 stabilization. Tmem27 levels and
Bace2 in its zymogen form increased already after 4 hr and
continued to rise with prolonged CpdJ incubation (Figure 6B)
with no signs of b cell death (data not shown). Together, these
data indicated that CpdJ is a potent inhibitor of Bace2 activity
in primary b cells in vitro.
We next tested if CpdJ displayed some of the anticipated
features of Bace2 inhibition in b cells. The biological conse-
quence of Tmem27 stabilization as a result of Bace2 inhibition
by CpdJ was first studied in proliferation assays. MIN6
cells were grown in the absence and presence of CpdJ, and
proliferation was measured by following EdU incorporation.
The proliferation of MIN6 cells increased upon CpdJ compared
to vehicle-treated cells (Figure 6C), and a similar increase in
proliferation was measured when Bace2, but not Bace1, was
inhibited by RNAi. The proliferation was reduced in CpdJ-
treated MIN6 cells in which Tmem27 was silenced, suggesting
that the effect of altered Bace2 levels is at least partly depen-
dent on Tmem27 expression (Figure 6C). Conversely, overex-
pression of Bace2 but not Bace1 led to decreased EdU incorpo-
ration that was reversible by the addition of CpdJ (Figure 6D).
The levels of Tmem27, Bace1, and Bace2 under all these condi-
tions were analyzed by western blot and revealed a robust
correlation between Bace2 levels and proliferation unless
Tmem27 was silenced (Figures 6E and 1E). To establish whether
the proliferative effect of CpdJ and its dependence on Tmem27
expression also held true in primary cells, murine islets were
dispersed and infected with a lentivirus expressing a nontarget-
ing short hairpin (shScramble) or a hairpin targeting Tmem27
(shTmem27). CpdJ or DMSO was added 24 hr later, and the
EdU incorporation into insulin-positive cells was determined
after further 48 hr. While CpdJ led to increased proliferation in
the control infected b cells, the decreased proliferation
observed in the cells infected with the Tmem27 targeting virus
could not be reversed by CpdJ incubation (Figure 6F). The effi-
ciency of RNAi and CpdJ was confirmed by western blot
(Figures S5C and S5D). Lastly, to study the extent to which
the proliferative effect of CpdJ was dependent on Bace2, we
dispersed Bace2DE6/DE6 islets and incubated them with CpdJ.
In line with the lack of further Tmem27 stabilization or Bace2
zymogen induction upon CpdJ incubation in these islets (Fig-
ure 6A), no further increase in proliferation was observed in
Bace2DE6/DE6 islets (Figure S5E). These findings demonstrate
that CpdJ is an effective Bace2 inhibitor that exhibits proprolifer-
ative activity in vitro that is at least partially dependent on
Tmem27 expression.Cell MeTo investigate if Bace2 inhibition has an acute effect on
pancreatic b cell function, we measured GSIS in primary mouse
islets. Isolated islets were incubated with CpdJ for 8 hr prior to
and during stimulation with increasing concentrations of
glucose. No changes in GSIS were measured in islets treated
with CpdJ compared to controls (Figure 6G), despite efficient
Bace2 inhibition and increased Tmem27 levels after 8 hr (Fig-
ure 6B). Even when islets were subjected to GSIS upon CpdJ
incubation after 24, 48, and 72 hr, no differences were observed
(data not shown). The independence of GSIS on short-term
Bace2 inhibition or Tmem27 levels was furthermore supported
by the fact that no difference in glucose or L-Arginine response
was observed when dispersed islets were infected with
shTmem27- or shScramble-expressing lentivirus and incubated
in the presence of CpdJ or DMSO prior to the assay (Figure S5F).
These data suggest that CpdJ does not act as an acute insulin
secretagogue.
Finally, we also tested if CpdJ exhibited proliferative and func-
tional effects in human pancreatic islets. Addition of CpdJ to the
culture medium of human islets led to the stabilization of FL
Tmem27 and the anticipated Bace2 prodomain shift (Figure 6H).
Although differentiated human b cells are thought to be slowly to
not proliferating and rather resistant to mitogenic stimuli in cell
culture (Efrat, 2008; Parnaud et al., 2008), we assessed the effect
of CpdJ on EdU incorporation into mature human b cells (i.e.,
cells with insulin-positive staining) from a 13- and a 60-year-
old female donor (donors A and B respectively). In donor A,
0.5% of the b cells within the dispersed islets were EdU positive
after a 60 hr incubation period, while proliferation of b cells from
donor B was an even rarer event (0.04% or 1 in 2500 b cells). The
addition of 100 nM CpdJ had no significant effect on the prolifer-
ation of b cells from either donor, although an overall tendency
toward more proliferation was perceived (Figure S5G). Similarly,
but in contrast to murine islets, human islets from the same
donors displayed the propensity to secrete more insulin upon
glucose stimulation when treated with CpdJ for 20 hr prior to
and during the assay (Figure S5H).
Taken together, CpdJ had similar biochemical and functional
effects on murine b cells in vitro as genetic Bace2 inactivation
in vivo: FL Tmem27 was stabilized, b cell proliferation was stim-
ulated, and insulin secretion was not affected after a short time
period, analogous to the lack of change in glucose levels in
Bace2DE6/DE6 mice up to the age of 7 weeks. Isolated human
islets were more resistant to the proliferative effect of CpdJ but
potentially more sensitive to the insulin secretory effect.
Pharmacological Inhibition of Bace2 Increases b Cell
Mass and Improves Glycemic Control in ob/ob Mice
We next investigated if daily intraperitoneal (i.p.) injection of
CpdJ would result in effective inhibition of Bace2 activity in vivo
and would therefore be suitable for metabolic studies. Initial PK
studies showed that CpdJ was rapidly cleared from the circula-
tion, with a t1/2 of 2 hr (Figure S5I). Nonetheless, wild-type mice
were treated with a single dose of either 30 or 100 mg/kg, and
Tmem27 stabilization and Bace2 prodomain shift were assayed
as readouts for Bace2 inhibition 24 hr later. A dose-dependent
stabilization of Tmem27 was measured in islet CL, and
a Bace2 prodomain shift was detected (Figure S5J), demon-
strating that the bioavailability of CpdJ was adequate totabolism 14, 365–377, September 7, 2011 ª2011 Elsevier Inc. 371
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Figure 5. Improved Blood Glucose Homeostasis and Increased b Cell Mass in Bace2DE6/DE6 Mice
(A) Weight of Bace2DE6/DE6 and Bace2+/+ littermate mice (n = 8–10).
(B) Ad libitum-fed blood glucose levels of Bace2DE6/DE6 and Bace2+/+ mice (n = 10–12).
(C) Blood glucose levels before (0 min) and after an i.p. glucose injection of 15-week-old Bace2DE6/DE6 and Bace2+/+ mice (n = 8–10).
(D) Serum insulin levels of 15-week-old Bace2DE6/DE6 and Bace2+/+ mice after a 6 hr fast (0 min) and after an intraperitoneal (i.p.) glucose injection (n = 12).
(E) Insulin released by isolated islets from 15-week-old Bace2DE6/DE6 and Bace2+/+ mice incubated at indicated glucose concentrations (n = 3). Insulin secreted
was normalized to total insulin content of secreting islets. This result was confirmed in two further independent experiments (data not shown).
(F) ITT of 15-week-old Bace2DE6/DE6 and Bace2+/+ mice using 0.5 U insulin/kg body weight (n = 12).
(G) b cell mass of 20-week-old Bace2DE6/DE6 and Bace2+/+ mice (n = 3). Mass was calculated by multiplying the fraction of b cell-positive surface area by
pancreatic wet weight.
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b Cell Protease Bace2determine the metabolic effect of pharmacological Bace2 inhibi-
tion of CpdJ in vivo. Toxicity of the compound was excluded,
since the serum levels of alanine transaminase and aspartate
transaminase during a 5 day treatment with either dose and
a 21 day treatment with 30 mg/kg CpdJ were unaltered
compared to vehicle treatment (data not shown).
We then sought to determine if administration of CpdJ could
improve glucose tolerance in a mouse model of obesity-related
insulin resistance, the ob/ob mice. CpdJ led to stabilization of
Tmem27 and to the Bace2 prodomain shift already 6 hr after
administration and up to 24 hr postadministration (Figure 7A),
indicating that a daily dose of 30 mg/kg body weight was suffi-
cient to reach constant Bace2 inhibition. This dose was well
tolerated and in contrast to the 100 mg/kg dose affected neither
body weight nor food intake (Figure 7B, data not shown). The
compound was administered for 21 days in 5-week-old ob/ob
mice with an IPGTT and an ITT performed at day 11 and 15,
respectively. Short-term fasting blood glucose levels started to
decrease after 1 week of treatment in CpdJ-treated mice com-
pared to vehicle-receiving controls (Figure 7C). Overnight fasting
blood glucose levels were also decreased at day 11 (Figure 7D).
The glucose clearance from the blood in CpdJ-treated mice was
improved compared to vehicle-treated animals during an IPGTT
(Figure 7D). Notably, plasma insulin levels during the IPGTT were
increased in CpdJ-treated mice at 15 and 30 min compared to
control-treated mice (Figure 7E). The ITT at day 15 revealed no
differences in the vehicle- versus CpdJ-treated group, thereby
demonstrating that CpdJ does not alter insulin sensitivity
(Figure 7F).
We next analyzed the effect of CpdJ on pancreatic b cell mass
by performing a morphometric analysis of CpdJ- and vehicle-
treated ob/ob mice after 21 days of treatment. The pancreatic
b cell mass in the CpdJ-treated group was larger than in the
vehicle-administered controls (Figure 7G), while the pancreatic
a cell mass was not changed (1.00 mg ± 0.13 and 1.04 mg ±
0.27 for vehicle- and CpdJ-treated groups, respectively). Immu-
nostaining of insulin-positive cells with anti-Ki67 antibody re-
vealed an increase in the number of Ki67-positive b cells in the
CpdJ-treated group compared to controls (Figure 7H), whereas
no apoptosis was observed (data not shown). Finally, to assess if
this proliferation effect was islet autonomous, EdU incorporation
into nuclei of insulin-positive cells in dispersed ob/ob islets was
analyzed upon CpdJ treatment compared to DMSO treatment
and was found to be elevated 2-fold (Figure 7I). While an
18 day treatment with CpdJ of wild-type mice had no effect on
glucose levels (data not shown), similar findings were observed
when C57BKSdb/db mice, which are known to have more severe
insulin secretion defects than ob/ob mice (Han et al., 2007; Roe
et al., 1994; Winzell et al., 2009), were subjected to the same
treatment regime (Figures S6A–S6H), suggesting that the effects
of CpdJ were not limited to the ob/obmodel. Together, our data(H) Total insulin content of pancreata from 20-week-old Bace2DE6/DE6 and Bace2
(I) a-cell mass of Bace2DE6/DE6 and Bace2+/+ mice (n = 3).
(J) Percentage of Ki67-positive b cell nuclei in Bace2DE6/DE6 and Bace2+/+ pancr
(K) Fold change of EdU-positive b cells in dispersedBace2DE6/DE6 islets compared
from four 12-week-old mice per genotype were analyzed, and at least 3000 b ce
Data shown in (A)–(C) and (F)–(I) came from the same cohort of animals. (D), (E), (J),
*p% 0.05; **p% 0.01; ***p% 0.001.
Cell Medemonstrate that CpdJ improves glycemic control by increasing
functional b cell mass in vivo.
DISCUSSION
In this study, we have identified Bace2 as one of the few
membrane proteases reported to be involved in the regulation
of pancreatic b cell mass and function. This is at the same time
the assignment of a biological function for Bace2.
Tmem27 is a Bace2-specific target, as the other known Bace2
substrates are also cleaved by Bace1, although frequently at
a different site. The fidelity of Tmem27 toward Bace2 rather
than Bace1 might in part be explained by the enrichment of
hydrophobic moieties in the cleavage site that has been found
in other Bace2 substrates and distinctively in domains in which
Bace1 did not cleave those proteins (Fluhrer et al., 2002; Grun-
inger-Leitch et al., 2002; Sun et al., 2006; Yan et al., 2001).
Another way by which the specificity of interaction of Tmem27
with Bace2 rather than Bace1 could be conferred is by differen-
tial compartmentalization: Bace1 is known to be resident
primarily in the Golgi-TGN compartments (Gandhi et al., 2004),
while Bace2 is localized to the endosomal compartments
(Fluhrer et al., 2002; Walter, 2006) and active at less acidic pH
than Bace1 (Kim et al., 2002).
The merits of inhibiting Bace2 were discovered in the quest
for a protease cleaving Tmem27. Since both overexpression
of Tmem27 (Akpinar et al., 2005; Fukui et al., 2005) and ablation
of Bace2 activity led to raised Tmem27 protein levels and each
setting increases b cell mass and function, it is likely that part of
these effects of inactivating Bace2 are mediated by Tmem27.
This notion is underpinned by a partial dependency of the
action of CpdJ on Tmem27 expression in its ability to stimulate
murine b cell proliferation. We did not observe such a depen-
dency of GSIS on Tmem27, consistent with the unaltered
insulin secretion from Tmem27 knockout islets (Malakauskas
et al., 2009). However, since only generic readouts for b cell
function, proliferation, and insulin secretion have been used to
measure Tmem27 activity, it is likely that Tmem27 primarily
acts upstream of both processes. Given its location at the inter-
face of the intra- and extracellular b cell environment, Tmem27
could possibly act as a sensor (Zhang et al., 2007) or, in
analogy to other g-secretase targets, as a scaffolding protein
regulating the plasticity of extracellular matrix and growth
hormone signaling (Cavallaro and Dejana, 2011). It is also
important to stress that Tmem27 represents only one of likely
many and yet-to-be-identified Bace2 b cell targets. This is sup-
ported by a recent study, which reported the identification of
about 60 Bace targets in HEK293 cells, including known posi-
tive regulators of b cell growth such as hepatocyte growth
factor receptor (Hemming et al., 2009). Therefore, it is to be
expected that a combination of PM Bace2 substrates will+/+ mice (n = 5–7).
eata from 7-week-old mice (n = 5).
toBace2+/+ islets after 60 hr incubation in presence of 10 mMEdU (n = 4). Islets
lls were counted per animal. Percentage of EdU-positive cells was 2.5%–4%.
and (K) each came from a separate set of animals. Data represent means ± SD.
tabolism 14, 365–377, September 7, 2011 ª2011 Elsevier Inc. 373
DMSO CpdJ DMSO CpdJ DMSO CpdJ DMSO CpdJ
Bace2
Tmem27
γ-Tubulin
Incubation
time
4h 8h 24h 72h
Tmem27
Bace2
γ-Tubulin
siC
trl
siT
me
m
27
+
siC
trl
siT
me
m
27
+
siB
ac
e2
siT
me
m
27
+ s
iBa
ce
1
siB
ac
e2
+ s
iCt
rl
siB
ac
e1
+
siC
trl
siT
me
m
27
+
Cp
dC
siT
m
em
27
+ C
pd
J
siT
me
m
27
+
DM
SO
DM
SO
siC
trl
+
Cp
dC
siC
trl
+
Cp
dJ
siC
trl
+
Bace1
Bace2+/+ Bace2ΔE6/ΔE6
DMSO CpdJ
200nM
DMSO CpdJ
200nM
γ -Tubulin
(CL) Tmem27
(SN) Tmem27
Bace2 60 kDa
46 kDa
48 kDa
25 kDa
In
su
lin
(pg
/h
)/n
gt
ot
a
li
ns
ul
in
0
50
100
150
200
250
DMSO
100 nM CpdJ (pretreatment & assay)
100 nM GLP-1 (assay only)
3.3 6.6 10 16.7Glucose (mM)
***
D
E
C
G
CpdJ (200 nM) _ _+ +
Donor 1 2
hTmem27
hBace2
hGAPDH
A B
sh
Sc
ram
ble
+D
MS
O
sh
Sc
ram
ble
+C
pd
J
sh
Tm
em
27
+D
MS
O
sh
Tm
em
27
+C
pd
J
***
*** **
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Fo
ld
ch
an
ge
Ed
U
po
si
tiv
e
βc
e
lls
F
%
Ed
U
po
sit
ive
ce
lls
0
2
4
6
8
10
12
siC
ont
ro
l
siT
m
em
27
siT
me
m2
7+
siB
ace
2
siT
me
m2
7+
siB
ac
e1
siB
ace
1+
siC
ont
rol
siB
ace
2+
siC
on
tro
l
siT
me
m2
7+
Cp
dC
siT
me
m2
7+
Cp
dJ
siT
me
m
27
+D
MS
O
siC
ont
rol+
Cp
dC
siC
ont
rol+
Cp
dJ
siC
ont
ro
l+D
MS
O
*** ***
***
*** *** ***
***
***
14
***
***
***
***
0
4
6
8
12
16
10
2
14
%
Ed
U
po
sit
ive
ce
lls
pc
DN
A3
+D
MS
O
pc
DN
A3
+C
pd
J
hB
ac
e2
+D
MS
O
hB
ac
e2
+C
pd
J
hB
ac
e1
+D
MS
O
hB
ac
e1
+C
pd
J
H
Figure 6. Pharmacological Inhibition of Bace2 and Its Effects on MIN6 Proliferation, Insulin Secretion, and Tmem27 and Bace2 Levels
in Isolated Islets
(A) Immunoblot of Tmem27 and Bace2 in SN and CL of isolated islets from 12-week-old Bace2DE6/DE6 and wild-type littermate control mice treated with 200 nM
CpdJ or DMSO for 48 hr. Note additional higher molecular weight band of Bace2 in wild-type lanes upon treatment with inhibitor, reflecting the Bace2 prodomain
shift occurring upon Bace2 inhibition.
(B) Western blot for Tmem27 and Bace2 in CL of isolated islets from 8-week-old mice treated with 100 nM CpdJ or DMSO after indicated incubation
time.
(C and D) Quantification of EdU incorporation (expressed as percentage of EdU-positive nuclei over total nuclei) of MIN6 cells upon treatment with 100 pmol of
siRNA (C) or 1 mg plasmid/ 106 cells (D) and 100 nM CpdJ or DMSO. On average, 7000 MIN6 nuclei were assessed per well. The experiment was done in three
independent repeats, 30 wells per group in total. All pairwise comparisons with the untreated group were highly significant (binomial linear mixed-effect model
with post hoc correction, p < 1016).
(E) Western blot for Tmem27, Bace1, and Bace2 in MIN6 CL after treatment with 100 pmol of siRNA and 100 nM CpdJ or DMSO.
(F) Fold change of EdU-positive b cells in dispersed islets from 4-week-old C57Bl6 mice infected with lentivirus expressing hairpin against Tmem27 (shTmem27)
compared to nontargeting hairpin (shScramble) (n = 4). Dispersed islets were incubated in the presence of 100 nMCpdJ or DMSO,whichwas added together with
EdU 24 hr postinfection, and cells were fixed 72 hr posttransfection. At least 3000 b cells were counted per animal. Percentage of EdU-positive and insulin positive
cells was 4%–7%.
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Figure 7. Improved Glucose Tolerance and
Increased b Cell Mass in ob/ob Mice Treated with
30 mg/kg CpdJ
(A) Western blot for Tmem27 and Bace2 protein of ob/ob
islets isolated 6 or 24 hr after a single i.p. injection in
5-week-old mice with vehicle or 30 mg/kg CpdJ. Note that
by densitrometric analysis the ratio of Bace2 zymogen to
mature Bace2 is increased 1.35-fold upon CpdJ after 6 hr,
and 1.15-fold after 24 hr, compared to vehicle treatment.
(B) Body weight of ob/obmice treatedwith 30mg/kg CpdJ
or vehicle from week 5 of age (n = 11).
(C) Blood glucose levels of ob/ob mice treated with
30 mg/kg CpdJ or vehicle after a 6 hr fast in the course of
18 days (n = 11).
(D) Blood glucose levels before (0 min, after 12 hr fast) and
after an i.p. glucose injection (1 g/kg body weight) in ob/ob
mice treated with 30 mg/kg CpdJ or vehicle for 11 days
(n = 11).
(E) Serum insulin levels after a 12 hr fast (0 min) and
an i.p. glucose injection (1g/kg body weight) in ob/ob
mice treated with 30 mg/kg CpdJ or vehicle for 11 days
(n = 11).
(F) ITT in ob/obmice treated with either 30 mg/kg CpdJ or
vehicle for 15 days, using 2U insulin/kg body weight (n = 6).
(G) Pancreatic b cell mass of ob/ob mice treated with
30 mg/kg CpdJ or vehicle for 20 days (n = 4). Mass was
calculated by multiplying the fraction of b cell-positive
surface area by pancreatic wet weight.
(H) Percentage of Ki67-positive b cell nuclei in pancreata of
ob/ob mice treated with 30 mg/kg CpdJ or vehicle for
20 days (n = 6).
(I) Fold change of EdU-positive b cells in dispersed ob/ob
islets from 5-week-old animals after 60 hr incubation in the
presence of 10 mM EdU and 100 nM CpdJ compared to
DMSO (n = 4). At least 3000 b cells were counted per
animal. Percentage of EdU-positive cells was 0.5%–1.5%.
Data shown in (B)–(H) were obtained from the same set of
animals and represent means ± SD. *p% 0.05; **p% 0.01;
***p% 0.001.
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function.
Although Bace2 inhibition leads to a rapid stabilization of
Tmem27 and a measurable effect on b cell proliferation within
days, we did not observe an acute effect on murine b cell insulin
secretion. This indicates that long-term reprogramming of the
murine islet may be required for the manifestation of the alter-
ation in b cell function, but the exact mechanism(s) and time
course remain to be elucidated—possibly by novel Bace2 target
identification. Although the preceding b cell proliferation and only
subsequent manifestation of enhanced b cell function upon
Bace2 inhibition are not necessarily causally linked, it seems
plausible that augmented b cell mass will contribute to the
improved b cell function.(G) In vitro insulin secretion of isolatedmurine islets from 12-week-oldmice (four b
GLP-1 (7-36) concentration. Islets were treated with 100 nM CpdJ or DMSO 8 h
(H) Western blot for hTmem27, and hBace2 in CL of human islets derived from two
SD. *p% 0.05; **p% 0.01; ***p% 0.001.
Cell MeIn human islets, CpdJ had no significant effect on b cell prolif-
eration under our experimental conditions, although Bace2
could be targeted, Tmem27 stabilized, and GSIS augmented
on a shorter timescale. Such species-to-species variations in
b cell properties have been observed previously (Maechler
et al., 2002), especially the resilience of human b cells to prolifer-
ative stimuli in vitro (Parnaud et al., 2008). Our data do suggest
that the basic Bace2-Tmem27 axis is conserved and that
Bace2 inhibition may lead to improved human b cell function.
One major limitation of such studies is the lack of in vivo
data in humans. However, given the more advanced Bace1
inhibitor programs in the Alzheimer’s disease research field,
our observations strongly encourage the measurement of glyce-
mic parameters during such studies. While the development ofatches of 25 islets per condition) incubated with the indicated glucose or human
r prior to and throughout assay.
donors after treatment with 200 nM of CpdJ for 72 hr. Data represent means ±
tabolism 14, 365–377, September 7, 2011 ª2011 Elsevier Inc. 375
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b Cell Protease Bace2Bace1-selective compounds has been challenging so far, our
studies suggest that nonselective inhibitors may even be desir-
able in attempts to prevent Alzheimer’s, since type 1 and type
2 diabetes (Park, 2011) represent major risk factors to devel-
oping this neurodegenerative disease.
EXPERIMENTAL PROCEDURES
Experimental Animals
All animalsweremaintained in a pathogen-free facility at the Institute forMolec-
ular Systems Biology, ETH Zu¨rich. The animals were kept on a 12 hr light/dark
cycle and fed a standard rodent chow diet (Kliba-Nafag) from 3 weeks of age.
Human Islets
Human islets were obtained through the Juvenile Diabetes Research Founda-
tion (JDRF) Islet Distribution Program. The use of human material was
approved through the ETH ethical committee.
Vectors
The hTmem27-encoding vectors were described previously (Akpinar et al.,
2005). The C-terminal deletion mutant of hTmem27 was generated by deleting
amino acid residues 171–222 using a PCR approach. The point mutations in
Bace2 were introduced using the QuickChange II XL site-directed mutagen-
esis kit (Stratagene). The Bace2DE6 construct was obtained by deleting
exon 6 using a PCR approach.
Cell Culture
MIN6 cells were maintained in DMEM containing 25 mM glucose, 15% FBS,
and 55 mM b-mercaptoethanol. HEK293 cells were grown on DMEM with
25 mM glucose and 10% FBS. Isolated murine islets were cultured in RPMI
with 11 mM glucose and 10% FBS, and human islets in CMRL with 5.6 mM
glucose and 10% FBS. For shedding experiments, the medium was
exchanged to Opti-MEM (Invitrogen).
RNA Interference Screen
SiRNAs against Tmem27 were used as described previously (Akpinar et al.,
2005). SiRNA smart pools containing four different sequences targeting each
proteasewerepurchased fromDharmacon (see theSupplementalExperimental
Procedures, Table S3). MIN6 cells were grown to 30% confluency and electro-
porated with 100 pmol siRNA/106 cells in AMAXA nucleofector V solution using
AMAXA single cuvette electroporator and program G-016 (available online at
http://www.amaxa.com/).Cellswereplated in6-well plates,and12hrafter elec-
troporation the medium was exchanged to Opti-MEM for another 24 hr.
Transient Transfection with Plasmids
MIN6 cells were transfected with 5 mg DNA/106 cells either by electroporation
(see above) or by using Lipofectamine 2000 (Invitrogen). HEK293 cells were
transfected with 1.5 mg DNA/106 cells using Fugene 6 (Roche) according to
the manufacturer’s protocol.
In Vitro Protease Inhibition
MIN6 cells were incubated with 100 mM of the BIOMOL inhibitors for 4 hr and
indicated doses of Cpd A, B, C, D, and J for 24–48 hr. DAPT was used at
1–10 mM for no longer than 16 hr. Isolated islets were incubated with 100 or
200 nM CpdJ for an indicated period of time.
In Vivo Administration of CpdJ
Mice were i.p. injected with 30 mg/kg or 100 mg/kg body weight of a 15 mg/ml
or 50 mg/ml solution of CpdJ in gelatin or vehicle (gelatin).
Statistical Analysis
All values are described as mean ± standard deviation (SD). Statistical signif-
icance was determined with a Student’s t test, rejecting the null hypothesis at
p = 0.05, with the exception of the analysis of the MIN6 proliferation assays,
whichwere evaluated by one-way ANOVA followed byDunnett’s post hoc test.376 Cell Metabolism 14, 365–377, September 7, 2011 ª2011 ElsevieSUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, three tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2011.06.018.
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